A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
IgA Nephropathy
About this trial
This is an interventional treatment trial for IgA Nephropathy focused on measuring IgA nephropathy
Eligibility Criteria
Inclusion Criteria:
- Subjects of either sex, more than 18 years old, the range of age is 18 to 70 year old.
- Biopsy-proven IgA nephropathy.
- Proteinuria between 0.15g/d and 3.0g/d; and serum albumin level>3.5g/dl.
- Serum creatinine < 3 mg/dl.
- Uric acid > 6 mg//dl (360umol/dl) in female; Uric acid >7mg/dl (420umol/dl ) in male.
- No history of taking ACEI or ARB within 2 weeks.
- Blood pressure < 180/110 mmHg.
- Subjects who agree to participate in the study and sign the informed consent.
Exclusion Criteria:
- Patients who have received prednisone or immunosuppressive drugs within 2 months.
- Patients who must take ACEI or ARB due to other diseases.
- Patients who have the history of allergy to allopurinol.
- Unwillingness to follow the study protocol.
- Active gout within 4 weeks.
- Pregnancy or unwillingness to use contraception.
Sites / Locations
- The 1st Affiliated Hospital, Sun Yet-sen University
Arms of the Study
Arm 1
Arm 2
Experimental
Other
Allopurinol
Control group
Allopurinol group:allopurinol, 100-300mg/d according to the levels of Scr(serum creatinine) and UA(uric acid), for those Scr < 1.5mg/dl (133 umol/L) at the baseline, allopurinol was given 100 mg three times daily.Patients diagnosed with hypertension received antihypertensive drugs with titration of CCB and β-blocker during the follow-up.The target of BP is less than 130/80mmHg.
Control group:(patient in this group were received health education and were encouraged to adhere to a low-purine diet and continue their usual therapy.Patients diagnosed with hypertension received antihypertensive drugs with titration of CCB and β-blocker during the follow-up.The target of BP is less than 130/80mmHg.